T cell receptor–major histocompatibility complex–LT peptide complex (TCR–MHC–LT peptide complex)

The T cell receptor–major histocompatibility complex–peptide complex is the central molecular unit required for T cell antigen recognition. The TCR is a highly diverse surface receptor on T lymphocytes that scans antigenic peptides presented by MHC molecules on antigen-presenting cells; these peptides may originate from pathogens, tumors, or self-proteins. MHC molecules are divided into class I and II, each presenting different types of peptides and engaging different T cell subsets (CD8+ for class I, CD4+ for class II). The peptide binds within a groove of the MHC molecule, with anchor residues dictating specificity. The assembled complex mediates T cell activation, launching immune defense or tolerance. Its structural and functional attributes make it a prime focus for biotechnology, structural modeling, and clinical therapeutics. Disruption or modulation of this complex is a key avenue in cancer immunotherapy, infection control, and autoimmunity management. Off-target recognition and inter-individual variation in MHC specificity represent significant safety and efficacy concerns. If the intent is to capture a specific complex (e.g., with LT peptide = SV40 large T antigen or a lymphotoxin peptide), this should be specified more precisely for ideal downstream structured data.

Other names

TCR–pMHC complexTCR–peptide–MHC complexTCR–HLA–peptide complex (in humans, “MHC” = “HLA”)T cell antigen recognition complex

TCR-engaging: Bind to TCR or block peptide-MHC interactions, often enhancing immune response against tumors/infected cells Peptide vaccine: Sequester or mimic the antigenic peptide within MHC to focus immune recognition Checkpoint blockade: Inhibit negative regulatory receptors, increasing TCR-MHC signaling